Cost-effectiveness analysis of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infections among premature infants, with different gestational ages;Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale

PharmacoEconomics - Italian Research Articles

Volumn 8, Issue 2, 2006, Pages 105-117

  Ravasio, Roberto ^a   Lucioni, C ^a   Chirico, G ^b  

^a Wolters Kluwer Health/ADIS International   (Italy)

^b SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; LUNG DYSPLASIA; PREMATURITY; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 33846796106     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320561     Document Type: Article

References (40)

1. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. Evaluation of the safety of Palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003; 26 (4): 283-91
2. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, editors. Textbook of Pediatric Infectious Diseases. Philadelphia (PA): Saunders, 1998: 2084-111
3. Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of Palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004; 23 (8): 707-12
4. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003; 88 (12): 1065-9
5. Sato M, Saito R, Sakai T, et al. Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons. J Clin Microbiol 2005; 43 (1): 36-40
6. Perkins SM, Webb DL, Torrance SA, et al. Comparison of a real-time reverse trancriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 2005; 43 (5): 2356-62
7. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York (NY): Churchill Livingstone, 1995: 1501-19
8. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis associated hospitalizations among US children, 1980-1996. JAMA 1999; 282 (15): 1440-6
9. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Child 1990; 144 (3): 346-8
10. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infections in children with bronchopulmonary dysplasia. Pediatrics 1988; 82 (2): 199-203
11. Boyce TG, Mellen BG, Mitchel EF, at al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137 (6): 865-70
12. Sito: www.vrsinfo.it
13. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143 (5 Suppl.): S150-6
14. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176 (5): 1215-24
15. Subramanian KNS, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998; 17 (2): 110-5
16. Saez-Llorens X, Castano E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998; 17 (2): 787-91
17. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3): 531-7
18. Società Italiana di Neonatologia. Raccomandazioni per la prevenzione della malattia da virus respiratorio sinciziale (RSV). Riv Ital Pediatr 2000; 26: 379-81
19. Macagno F. Main results of a national multicenter study assessing the compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of Respiratory Syncytial Virus infection. Pediatr Med Chir 2005; 27 (Suppl. 2): S10-20
20. Simoes EAF. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002; 3 (Suppl. 1): S26-33
21. Simoes EAF, Carbonell-Estrany X, Kimpen J, et al. Palavizumab use decreases risk of recurrent wheezing in preterm children. Abstract presented at 14th ERS Annual Congress. Glasgow, September 4-8, 2004
22. Giovannini M, Rossi GA, Merolla R. Patologia respiratoria in bambini ospedalizzati nei primi due anni di vita per infezioni virali delle basse vie respiratorie: 1 anno di follow-up. Minerva Pediatr 2003; 55 (2): 149-55
23. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalization for RSV infection. Arch Dis Child 2001; 85 (6): 463-8
24. Pedersen O, Herskind AM, Kamper J, et al. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediatr 2003; 92 (2): 240-2
25. Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137 (6): 865-70
26. Emond A, Evans J-A, Howat P. The continuing morbidity and use of health services by preterm infants after discharge from hospital. Ambulat Child Health 1997; 3: 121-9
27. Kinali M, Greenough A, Dimitriou G, et al. Chronic respiratory morbidity following premature delivery - prediction of prolonged respiratory support requirement. Eur J Pediatr 1999; 158 (6): 493-6
28. Fleming MD, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 2005; 59 (7): 586-90
29. Gomez R, Colas C, Sebastian A, et al. Respiratory repercussions in adults with a history of infantile bronchiolitis. Ann Allergy Asthma Immunol 2004; 93 (5): 447-51
30. Lemanske RF. Viral infections and asthma inception. J Allergy Clin Immunol 2004; 114 (5): 1023-6
31. Sigurs N, Gustafsson PM, Bjarnason R. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171 (2): 137-41
32. Singleton RJ, Redding GJ, Lewis TC. Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska native children. Pediatrics 2003; 112 (2): 285-90
33. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89 (7): 673-8
34. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Med Care 1996; 34 (7): 702-22
35. Dal Negro RW, Turco P, Canonica WG, et al. Progetto S.I.R.I.O. (Social Impact of Respiratory Integrated Outcomes)-Ricerca multicentrica nazionale sui costi generati dalle malattie respiratorie. Atti del V Congresso Nazionale di Medicina Respiratoria. Milano, 6-9 ottobre 2004
36. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. (Ed. it. a cura di Fattore G, Garattini L, Lucioni C). Metodi per la valutazione economica dei programmi sanitari. Roma: Il Pensiero Scientifico Editore, 2000
37. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 (Suppl. 4): 5-10
38. Nuijten MJ, Lebmeier M, Daalderop P, et al. Cost-effectiveness model of Palivizumab in the Netherlands. Value Health 2005; 8 (6): abstract PIH1
39. Nuijten MJ, Lebmeier M, Wittemberg W. Cost-effectiveness model of Palivizumab in the UK. Value Health 2005; 8 (6): abstract PIN23
40. Lozano P, Sullivan SD, Smith DH, et al. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999; 104 (5): 957-63